- Home
- GCBC vs ANL Comparison
GCBC vs ANL Comparison
Compare GCBC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | GCBC | ANL |
|---|---|---|
| Founded | 1889 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.8M | 406.5M |
| IPO Year | 1998 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GCBC | ANL |
|---|---|---|
| Price | $23.70 | $13.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 10.5K | ★ 390.4K |
| Earning Date | 04-20-2026 | 04-20-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | ★ 26.21 | N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $4,117,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.78 | ★ N/A |
| Revenue Growth | ★ 11.06 | N/A |
| 52 Week Low | $20.62 | $0.88 |
| 52 Week High | $26.04 | $15.79 |
Technical Indicators
Market Signals| Indicator | GCBC | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 60.26 | 70.05 |
| Support Level | $22.79 | $1.36 |
| Resistance Level | $25.09 | N/A |
| Average True Range (ATR) | 0.59 | 1.99 |
| MACD | 0.12 | 0.73 |
| Stochastic Oscillator | 75.22 | 81.38 |
Price Performance
Historical ComparisonAbout GCBC Greene County Bancorp Inc.
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.